TY - JOUR AU - Pártos, Katalin AU - Major, Dávid AU - Dósa, Norbert Sándor AU - Fazekas-Pongor, Vince AU - Tabák, Ádám AU - Ungvári, Zoltán AU - Horváth, Ildikó AU - Barta, Ildikó AU - Pozsgai, Éva AU - Bodnár, Tamás AU - Fehér, Gergely AU - Lenkey, Zsófia AU - Fekete, Mónika AU - Springó, Zsolt TI - Diagnosis rates, therapeutic characteristics, lifestyle, and cancer screening habits of patients with diabetes mellitus in a highly deprived region in Hungary: a cross-sectional analysis JF - FRONTIERS IN ENDOCRINOLOGY J2 - FRONT ENDOCRINOL VL - 15 PY - 2024 SN - 1664-2392 DO - 10.3389/fendo.2024.1299148 UR - https://m2.mtmt.hu/api/publication/34830215 ID - 34830215 LA - English DB - MTMT ER - TY - JOUR AU - Heeke, Simon AU - Gay, Carl M. AU - Estecio, Marcos R. AU - Tran, Hai AU - Morris, Benjamin B. AU - Zhang, Bingnan AU - Tang, Ximing AU - Raso, Maria Gabriela AU - Rocha, Pedro AU - Lai, Siqi AU - Arriola, Edurne AU - Hofman, Paul AU - Hofman, Veronique AU - Kopparapu, Prasad AU - Lovly, Christine M. AU - Concannon, Kyle AU - De Sousa, Luana Guimaraes AU - Lewis, Whitney Elisabeth AU - Kondo, Kimie AU - Hu, Xin AU - Tanimoto, Azusa AU - Vokes, Natalie I. AU - Nilsson, Monique B. AU - Stewart, Allison AU - Jansen, Maarten AU - Horváth, Ildikó AU - Gaga, Mina AU - Panagoulias, Vasileios AU - Raviv, Yael AU - Frumkin, Danny AU - Wasserstrom, Adam AU - Shuali, Aharona AU - Schnabel, Catherine A. AU - Xi, Yuanxin AU - Diao, Lixia AU - Wang, Qi AU - Zhang, Jianjun AU - Van Loo, Peter AU - Wang, Jing AU - Wistuba, Ignacio I. AU - Byers, Lauren A. AU - Heymach, John V. TI - Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes JF - CANCER CELL J2 - CANCER CELL VL - 42 PY - 2024 IS - 2 SP - 225 EP - 237.e5 SN - 1535-6108 DO - 10.1016/j.ccell.2024.01.001 UR - https://m2.mtmt.hu/api/publication/34788186 ID - 34788186 N1 - Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Epigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, United States Medical Oncology Department, Hospital del Mar, Barcelona, Spain Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHealth Houston, Houston, TX, United States Laboratory of Clinical and Experimental Pathology, IHU RespirERA, Nice Hospital, University Côte d'Azur, Nice, France Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, United States Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Pulmonary Department, Ziekenhuisgroep Twente, Hengelo, Netherlands National Korányi Institute of Pulmonology, Budapest, Hungary 7th Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece 2nd Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece Department of Medicine, Pulmonology, Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel Nucleix Ltd. Rehovot, Israel Nucleix Inc, San Diego, CA, United States Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, United States The Francis Crick Institute, London, United Kingdom Cited By :1 Export Date: 16 April 2024 CODEN: CCAEC Correspondence Address: Byers, L.A.; Department of Thoracic/Head & Neck Medical Oncology, United States; email: lbyers@mdanderson.org Correspondence Address: Heymach, J.V.; Department of Thoracic/Head & Neck Medical Oncology, United States; email: jheymach@mdanderson.org Chemicals/CAS: ademetionine, 29908-03-0, 485-80-3; DNA (cytosine 5) methyltransferase; DNA (cytosine 5) methyltransferase 1; DNA methyltransferase 3A; DNA methyltransferase 3B; histone lysine methyltransferase, 9076-80-6; methionine adenosyltransferase, 9012-52-6; Biomarkers, Tumor; Cell-Free Nucleic Acids Funding details: National Institutes of Health, NIH, CA217450, CA224276, CA233259 Funding details: National Cancer Institute, NCI, 1R50CA265307, CA016672, P50CA070907, R01CA207295, R50CA243698, SCLC U01CA213273, SCLC U01CA256780, U24CA213274 Funding details: Cancer Prevention and Research Institute of Texas, CPRIT, 120348, 170002, RP210159 Funding details: Albert Einstein Cancer Center, AECC Funding details: Wellcome Trust, WT, RR210006 Funding details: Rexanna's Foundation Funding details: Medical Research Council, MRC Funding details: Cancer Research UK, CRUK, CC2008 Funding details: European Society for Medical Oncology, ESMO Funding details: Horizon 2020, 829218 Funding details: Sociedad Española de Oncología Médica, SEOM Funding text 1: Funding has been provided by the NIH ; NIH/ NCI Core grant CA016672 (ATGC), NIH/NCI U24CA213274 , NIH/NCI SCLC U01CA213273 , NIH/NCI SCLC U01CA256780 , NCI/NIH R01CA207295 , NIH/NCI P50CA070907 , NIH/NCI R50CA243698 , NIH/NCI P30CA016672 ; 1R50CA265307 , and NIH Cancer Center Support Grand (CCSG)- Bioinformatics Shared Resources (BISR); the CPRIT Core Facility Support Grants ( #RP120348 and #RP170002 ), CPRIT Early Clinical Investigator Award ( RP210159 ), LUNGevity Career Development Award, the Horizon 2020 research and innovation program ( #829218 ); the AnnaRose King Cancer Research Fund , and the Camp fund, the Bruton endowment, John and Debbie Lyon Small Cell Lung Cancer Research fund and Rexanna's Foundation for Fighting Lung Cancer. This work was supported through generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Lung Cancer Moonshot Program. BBM is a TRIUMPH Fellow in the CPRIT Research Training Program ( RP210028 ). C.M.L was supported by National Institutes of Health grant numbers CA217450 , CA224276 , and CA233259 . PR was partially funded by ESMO , SEOM , and AECC . PVL was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK ( CC2008 ), the UK Medical Research Council ( CC2008 ), and the Wellcome Trust ( CC2008 ). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation’s support toward the establishment of The Francis Crick Institute. P.V.L. is a CPRIT Scholar in Cancer Research and acknowledges CPRIT grant support ( RR210006 ). The authors would like to thank the MDACC ATGC core facility as well as the MDACC Epigenetics core for supporting this project. Furthermore, the authors would like to thank Dr. Revital Knirsh and Orna Savin for their support in the laboratory. LA - English DB - MTMT ER - TY - JOUR AU - Örlős, Zoltán AU - Miklós, Zsuzsanna AU - Horváth, Ildikó TI - A COVID–19-fertőzéssel és -immunizációval szerzett tapasztalatok felnőtt cystás fibrosisos betegcsoportban JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 9 SP - 332 EP - 337 PG - 6 SN - 0030-6002 DO - 10.1556/650.2024.32994 UR - https://m2.mtmt.hu/api/publication/34724154 ID - 34724154 AB - Bevezetés: Habár a nem transzplantált, cystás fibrosisban szenvedő betegek többségében enyhe lefolyást mutat a COVID–19-fertőzés, a betegek kis hányadában súlyos lefolyású kórforma alakul ki. Célkitűzés: A célok között szerepelt azoknak a rizikófaktoroknak az azonosítása, amelyek megnövelik a koronavírussal fertőzött cystás fibrosisos betegek hospitalizációs igényét, emellett a betegek átoltottságát és a fertőzésben alkalmazott kezeléseket is vizsgálni kívántuk. Módszer: Az Országos Korányi Pulmonológiai Intézet Cystás Fibrosis Részlegén gondozott 145 beteg adatait elemeztük retrospektív módon a pandémia kitörése és 2022. december 31. között. Eredmények: A vizsgált időszakban a betegek 85,5%-a részesült SARS-CoV-2-alapimmunizációban, a beadott védőoltások 70,9%-a mRNS-alapú volt. A betegek 49,65%-a vészelte át a fertőzést, a fertőzöttek 13,9%-a kórházi ellátást igényelt. A súlyos lefolyású COVID–19 legfontosabb prediktora az erőltetett kilégzési másodpercvolumen (FEV 1 ) 35%-os vagy annál alacsonyabb értéke (OR: 6,25, p = 0,01). Megbeszélés: Vizsgálati eredményeink azt mutatják, hogy súlyos, kórházi ellátást igénylő COVID–19-fertőzés gyakrabban alakul ki az eleve kisebb FEV 1 -értékkel rendelkező cystás fibrosisos betegek körében. Felmérésünk alapján a felnőtt cystás fibrosisos betegek oltási fegyelme jelentősen meghaladja az országos átlagot, többségük már emlékeztető oltásban is részesült. Következtetés: A prediktorok ismerete segíthet meghatározni azokat a cystás fibrosisos betegeket, akiknél fokozott figyelem és gyors terápiás döntéshozatal szükséges COVID–19-infekció akvirálása esetén. Orv Hetil. 2024; 165(9): 332–337. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Sárközi, Anna Teréz AU - Tornyi, Ilona AU - Békési, Erik AU - Horváth, Ildikó TI - Co-Morbidity Clusters in Post-COVID-19 Syndrome JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 5 SP - 1457 SN - 2077-0383 DO - 10.3390/jcm13051457 UR - https://m2.mtmt.hu/api/publication/34720912 ID - 34720912 AB - Background: Post-COVID-19 syndrome, characterized by persistent symptoms emerging more than 12 weeks after acute infection, displays diverse manifestations. This study aimed to analyze co-existing organ dysfunctions in post-COVID-19 patients and explore their potential association with the acute COVID-19 episode and functional impairment. Methods: Data from 238 patients attending post-COVID-19 outpatient care between 1 March 2021 and 1 March 2022, after previous hospitalization for acute COVID-19, were retrospectively analyzed with 80 having comprehensive mapping of organ involvement. Results: The average time between acute episode and post-COVID-19 care was 149 days. Spirometry indicated significant abnormalities in lung function. Predominant symptoms included respiratory (75%), fatigue (73%), neurological (62.5%), and ear-nose-throat issues (51.25%). Multiorgan dysfunctions were observed in 87.5% of patients, contributing to an 18.33% reduction in health quality compared to pre-acute COVID-19 levels. Subgroup analysis identified four distinct post-COVID-19 syndrome subgroups, highlighting the coexistence of respiratory and neurological disorders as potential indicators and drivers of further organ involvement. Our results reveal that most patients with post-COVID-19 syndrome suffer from multiorgan disorders. Conclusions: The presence of coexisting respiratory and neurological symptoms suggests the involvement of other organ systems as well. The complexity of multiorgan involvement requires further studies to provide insights into the different symptom clusters and identify potential targets for personalized preventive and therapeutic interventions to improve patient outcome. LA - English DB - MTMT ER - TY - JOUR AU - Yasinska, V. AU - Gómez, C. AU - Kolmert, J. AU - Ericsson, M. AU - Pohanka, A. AU - James, A. AU - Andersson, L.I. AU - Sparreman-Mikus, M. AU - Sousa, A.R. AU - Riley, J.H. AU - Bates, S. AU - Bakke, P.S. AU - Kermani, N.Z. AU - Caruso, M. AU - Chanez, P. AU - Fowler, S.J. AU - Geiser, T. AU - Howarth, P.H. AU - Horváth, Ildikó AU - Krug, N. AU - Montuschi, P. AU - Sanak, M. AU - Behndig, A. AU - Shaw, D.E. AU - Knowles, R.G. AU - Dahlén, B. AU - van, der Zee A.-H.M. AU - Sterk, P.J. AU - Djukanovic, R. AU - Adcock, I.M. AU - Chung, K.F. AU - Wheelock, C.E. AU - Dahlén, S.-E. AU - Jonsson, E.W. TI - Low levels of endogenous anabolic androgenic steroids in females with severe asthma taking corticosteroids JF - ERJ OPEN RESEARCH J2 - ERJ OPEN RES VL - 9 PY - 2023 IS - 5 PG - 15 SN - 2312-0541 DO - 10.1183/23120541.00269-2023 UR - https://m2.mtmt.hu/api/publication/34210255 ID - 34210255 AB - Rationale Patients with severe asthma are dependent upon treatment with high doses of inhaled corticosteroids (ICS) and often also oral corticosteroids (OCS). The extent of endogenous androgenic anabolic steroid (EAAS) suppression in asthma has not previously been described in detail. The objective of the present study was to measure urinary concentrations of EAAS in relation to exogenous corticosteroid exposure. Methods Urine collected at baseline in the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease outcomes) study of severe adult asthmatics (SA, n=408) was analysed by quantitative mass spectrometry. Data were compared to that of mild-to-moderate asthmatics (MMA, n=70) and healthy subjects (HC, n=98) from the same study. Measurements and main results The concentrations of urinary endogenous steroid metabolites were substantially lower in SA than in MMA or HC. These differences were more pronounced in SA patients with detectable urinary OCS metabolites. Their dehydroepiandrosterone sulfate (DHEA-S) concentrations were <5% of those in HC, and cortisol concentrations were below the detection limit in 75% of females and 82% of males. The concentrations of EAAS in OCS-positive patients, as well as patients on high-dose ICS only, were more suppressed in females than males (p<0.05). Low levels of DHEA were associated with features of more severe disease and were more prevalent in females (p<0.05). The association between low EAAS and corticosteroid treatment was replicated in 289 of the SA patients at follow-up after 12–18 months. Conclusion The pronounced suppression of endogenous anabolic androgens in females might contribute to sex differences regarding the prevalence of severe asthma. © The authors 2023. LA - English DB - MTMT ER - TY - JOUR AU - Abdel-Aziz, M.I. AU - Thorsen, J. AU - Hashimoto, S. AU - Vijverberg, S.J.H. AU - Neerincx, A.H. AU - Brinkman, P. AU - Van, Aalderen W. AU - Stokholm, J. AU - Rasmussen, M.A. AU - Roggenbuck-Wedemeye, M. AU - Vissing, N.H. AU - Mortensen, M.S. AU - Brejnrod, A.D. AU - Fleming, L.J. AU - Murray, C.S. AU - Fowler, S.J. AU - Frey, U. AU - Bush, A. AU - Singer, F. AU - Hedlin, G. AU - Nordlund, B. AU - Shaw, D.E. AU - Chung, K.F. AU - Adcock, I.M. AU - Djukanovic, R. AU - Auffray, C. AU - Bansal, A.T. AU - Sousa, A.R. AU - Wagers, S.S. AU - Chawes, B.L. AU - Bønnelykke, K. AU - Sørensen, S.J. AU - Kraneveld, A.D. AU - Sterk, P.J. AU - Roberts, G. AU - Bisgaard, H. AU - Maitland-Van, Der Zee A.H. AU - Kolmert, J. AU - James, A. AU - Sousa, A.R. AU - Riley, J.H. AU - Bates, S. AU - Bakke, P.S. AU - Caruso, M. AU - Chanez, P. AU - Fowler, S.J. AU - Geiser, T. AU - Howarth, P. AU - Horváth, Ildikó AU - Krug, N. AU - Montuschi, P. AU - Sanak, M. AU - Behndig, A. AU - Shaw, D.E. AU - Knowles, R.G. AU - Holweg, C.T.J. AU - Wheelock, A.M. AU - Dahlen, B. AU - Alving, K. AU - Chung, K.F. AU - Adcock, I.M. AU - Sterk, P.J. AU - Djukanovic, R. AU - Dahlen, S.-E. AU - Wheelock, C.E. AU - Andersson, L. AU - Auffray, C. AU - Bisgaard, H. AU - De, Meulder B. AU - Fleming, L.J. AU - Frey, U. AU - Lutter, R. AU - Mumby, S. AU - Roberts, G. AU - Uddin, M. AU - Wagers, S.S. AU - Kermani, N.Z. AU - U-BIOPRED, Study Group TI - Oropharyngeal Microbiota Clusters in Children with Asthma or Wheeze Associate with Allergy, Blood Transcriptomic Immune Pathways, and Exacerbation Risk JF - AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE J2 - AM J RESP CRIT CARE VL - 208 PY - 2023 IS - 2 SP - 142 EP - 154 PG - 13 SN - 1073-449X DO - 10.1164/rccm.202211-2107OC UR - https://m2.mtmt.hu/api/publication/34206422 ID - 34206422 N1 - Department of Pulmonary Medicine, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands Department of Paediatric Pulmonary Medicine, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands AmsterdamPublic Health, Amsterdam, Netherlands Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, Copenhagen, Denmark Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, Copenhagen, Denmark Section of Microbiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark Department of Food Science, University of Copenhagen, Frederiksberg, Denmark Novozymes, Bagsvaerd, Denmark Section of Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark National Heart and Lung Institute, Imperial College London, London, United Kingdom Royal Brompton and Harefield NHS Trust, London, United Kingdom Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom Manchester Academic Health Science Centre, National Institute for Health and Care Research Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom University Children's Hospital Basel, University of Basel, Basel, Switzerland Division of Paediatric Pulmonology and Allergology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden National Institute for Health and Care, Research Respiratory Biomedical Research Unit, University of Nottingham, Nottingham, United Kingdom National Institute for Health and Care, Research Southampton Biomedical Research Centre, University Hospital Southampton, NHS Foundation Trust and Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, United Kingdom European Institute for Systems Biology AndMedicine, CIRI UMR5308, CNRS-ENS-UCBL-INSERM, Lyon, France Acclarogen Ltd., St. John's Innovation Centre, Cambridge, United Kingdom Respiratory Therapeutic Unit, GlaxoSmithKline, Stockley Park, United Kingdom BioSci Consulting, Maasmechelen, Belgium Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands Cited By :1 Export Date: 19 October 2023 CODEN: AJCME Correspondence Address: Maitland-Van der Zee, A.H.; Department of Pulmonary Medicine, Netherlands; email: a.h.maitland@amsterdamumc.nl Chemicals/CAS: salbutamol, 18559-94-9, 35763-26-9 Tradenames: HT HG-U133+, Affymetrix; MiSeq, Illumina Manufacturers: Affymetrix; Illumina AB - Rationale: Children with preschool wheezing or school-age asthma are reported to have airway microbial imbalances. Objectives: To identify clusters in children with asthma or wheezing using oropharyngeal microbiota profiles. Methods: Oropharyngeal swabs from the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes) pediatric asthma or wheezing cohort were characterized using 16S ribosomal RNA gene sequencing, and unsupervised hierarchical clustering was performed on the Bray-Curtis b-diversity. Enrichment scores of the Molecular Signatures Database hallmark gene sets were computed from the blood transcriptome using gene set variation analysis. Children with severe asthma or severe wheezing were followed up for 12-18 months, with assessment of the frequency of exacerbations. Measurements and Main Results: Oropharyngeal samples from 241 children (age range, 1-17 years; 40% female) revealed four taxa-driven clusters dominated by Streptococcus, Veillonella, Rothia, and Haemophilus. The clusters showed significant differences in atopic dermatitis, grass pollen sensitization, FEV1% predicted after salbutamol, and annual asthma exacerbation frequency during follow-up. The Veillonella cluster was the most allergic and included the highest percentage of children with two or more exacerbations per year during follow-up. The oropharyngeal clusters were different in the enrichment scores of TGF-b (transforming growth factor-β) (highest in the Veillonella cluster) and Wnt/β-catenin signaling (highest in the Haemophilus cluster) transcriptomic pathways in blood (all q values ,0.05). Conclusions: Analysis of the oropharyngeal microbiota of children with asthma or wheezing identified four clusters with distinct clinical characteristics (phenotypes) that associate with risk for exacerbation and transcriptomic pathways involved in airway remodeling. This suggests that further exploration of the oropharyngeal microbiota may lead to novel pathophysiologic insights and potentially new treatment approaches. Copyright © 2023 by the American Thoracic Society. LA - English DB - MTMT ER - TY - JOUR AU - Tornyi, Ilona AU - Árkosy, Péter AU - Horváth, Ildikó AU - Furka, Andrea TI - A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with “bone-only” metastatic breast cancer JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 29 PY - 2023 SP - 1 PG - 8 SN - 1219-4956 DO - 10.3389/pore.2023.1611369 UR - https://m2.mtmt.hu/api/publication/34188757 ID - 34188757 AB - The vast majority of hormone positive and HER2 negative advanced breast cancers can be controlled well by endocrine therapy combined with the groundbreaking use of CDK4/6 inhibitors in the metastatic first-line setting. Approximately 50%–60% of these patients have “bone-only” metastatic disease. In oligometastatic cases or if a certain number of uncontrolled lesions develop during the aforementioned therapy, ablative radiotherapy can be delivered or, in symptomatic cases, urgent irradiation is needed with palliative intent. To achieve the most effective results, parallel with good quality of life, the timing of radiotherapy must be determined precisely, taking into account that different cell cycles are involved during different treatment modalities; therefore, optimization of treatment schedules ensures longer and safer post-progression overall survival. The key question is whether the two treatment modalities are safe concurrently or whether they should be administered separately, and if so, what is the optimal sequence and why? This manuscript aims to answer this important question, with a focus on quality of life. Existing publications focus on safety and toxicity profiles, and efficacy is detailed only tangentially and minimally. LA - English DB - MTMT ER - TY - JOUR AU - Miklós, Z. AU - Horváth, Ildikó TI - The Role of Oxidative Stress and Antioxidants in Cardiovascular Comorbidities in COPD JF - ANTIOXIDANTS J2 - ANTIOXIDANTS-BASEL VL - 12 PY - 2023 IS - 6 PG - 29 SN - 2076-3921 DO - 10.3390/antiox12061196 UR - https://m2.mtmt.hu/api/publication/34064075 ID - 34064075 N1 - Export Date: 8 January 2024 Correspondence Address: Horváth, I.; National Korányi Institute for Pulmonology, Korányi F. Street 1, Hungary; email: ildiko.horvath@koranyi.hu LA - English DB - MTMT ER - TY - JOUR AU - Hou, R. AU - Ye, G. AU - Cheng, X. AU - Shaw, D.E. AU - Bakke, P.S. AU - Caruso, M. AU - Dahlen, B. AU - Dahlen, S.-E. AU - Fowler, S.J. AU - Horváth, Ildikó AU - Howarth, P. AU - Krug, N. AU - Montuschi, P. AU - Sanak, M. AU - Sandström, T. AU - Auffray, C. AU - De, Meulder B. AU - Sousa, A.R. AU - Adcock, I.M. AU - Fan, Chung K. AU - Sterk, P.J. AU - Skipp, P.J. AU - Schofield, J. AU - Djukanović, R. ED - Gálffy, Gabriella / Collaborator ED - Szentkereszty, Márton / Collaborator ED - Tamási, Lilla / Collaborator AU - Weiszhar, Zsóka TI - The role of inflammation in anxiety and depression in the European U-BIOPRED asthma cohorts JF - BRAIN BEHAVIOR AND IMMUNITY J2 - BRAIN BEHAV IMMUN VL - 111 PY - 2023 SP - 249 EP - 258 PG - 10 SN - 0889-1591 DO - 10.1016/j.bbi.2023.04.011 UR - https://m2.mtmt.hu/api/publication/33823988 ID - 33823988 N1 - Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom Suzhou Guangji Hospital, Jiangsu, Suzhou, China Shandong Mental Health Centre, Shandong, China Respiratory Research Unit, University of Nottingham, Nottingham, United Kingdom Department of Clinical Science, University of Bergen, Bergen, Norway Dept of Clinical and Experimental, Medicine Hospital University, University of Catania, Catania, Italy The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden Faculty of Biology, Medicine and Health, School of Biological Sciences, Division of Infection, Immunity & Respiratory Medicine, The University of Manchester and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Unit and Manchester University NHS Foundation Trust, United Kingdom Dept of Pulmonology, Semmelweis University, Budapest, Hungary Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, Germany Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland Department of Medicine, Department of Public Health and Clinical Medicine Respiratory Medicine Unit, Umea University, Sweden European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Université de Lyon, France Respiratory Therapeutic Unit, GlaxoSmithKline, Stockley Park, United Kingdom National Heart and Lung Institute, Imperial College London, United Kingdom Amsterdam UMC, University of Amsterdam, Holland, Netherlands Biological Sciences, University of Southampton, Southampton, United Kingdom NIHR Southampton Respiratory Biomedical Research Centre, United Kingdom Cited By :1 Export Date: 23 January 2024 CODEN: BBIME Correspondence Address: Hou, R.; Clinical and Experimental Sciences, 4-12 Terminus Terrace, United Kingdom; email: r.hou@soton.ac.uk Chemicals/CAS: gamma interferon, 82115-62-6; gamma interferon inducible protein 10, 97741-20-3; interleukin 13, 148157-34-0; interleukin 18, 189304-55-0; interleukin 8, 114308-91-7; macrophage inflammatory protein 1beta, 122071-81-2; thymus and activation regulated chemokine, 181532-29-6; Biomarkers; Interleukin-6 LA - English DB - MTMT ER - TY - JOUR AU - Brandsma, J. AU - Schofield, J.P.R. AU - Yang, X. AU - Strazzeri, F. AU - Barber, C. AU - Goss, V.M. AU - Koster, G. AU - Bakke, P.S. AU - Caruso, M. AU - Chanez, P. AU - Dahlén, S.-E. AU - Fowler, S.J. AU - Horváth, Ildikó AU - Krug, N. AU - Montuschi, P. AU - Sanak, M. AU - Sandström, T. AU - Shaw, D.E. AU - Chung, K.F. AU - Singer, F. AU - Fleming, L.J. AU - Adcock, I.M. AU - Pandis, I. AU - Bansal, A.T. AU - Corfield, J. AU - Sousa, A.R. AU - Sterk, P.J. AU - Sánchez-García, R.J. AU - Skipp, P.J. AU - Postle, A.D. AU - Djukanović, R. TI - Stratification of asthma by lipidomic profiling of induced sputum supernatant JF - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY J2 - J ALLERGY CLIN IMMUN VL - 152 PY - 2023 IS - 1 SP - 117 EP - 125 PG - 9 SN - 0091-6749 DO - 10.1016/j.jaci.2023.02.032 UR - https://m2.mtmt.hu/api/publication/33789491 ID - 33789491 N1 - Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom National Institute for Health Research Southampton Biomedical Research Centre, Southampton, United Kingdom Centre for Proteomic Research, Biological Sciences, University of Southampton, Southampton, United Kingdom Data Science Institute, Imperial College, London, United Kingdom Mathematical Sciences, University of Southampton, Southampton, United Kingdom Department of Clinical Science, University of Bergen, Bergen, Norway Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy Department of Respiratory Diseases, Aix-Marseille University, Marseille, France Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, Manchester, United Kingdom Manchester Academic Health Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom Department of Pulmonology, Semmelweis University, Budapest, Hungary Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy National Heart and Lung Institute, Imperial College, London, United Kingdom Department of Medicine, Jagiellonian University, Krakow, Poland Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden National Institute for Health Research Biomedical Research Unit, University of Nottingham, Nottingham, United Kingdom Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland Department of Paediatrics and Adolescent Medicine, Division of Paediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria Acclarogen Ltd, St John's Innovation Centre, Cambridge, United Kingdom Areteva Ltd, Nottingham, United Kingdom Respiratory Therapy Unit, GlaxoSmithKline, London, United Kingdom Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands Export Date: 21 October 2023 CODEN: JACIB Correspondence Address: Brandsma, J.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720B Rockledge Dr; email: JBrandsma@aceso-sepsis.org Chemicals/CAS: cholesterol, 57-88-5; DNA (cytosine 5) methyltransferase; DNA (cytosine 5) methyltransferase 1; DNA methyltransferase 3A; DNA methyltransferase 3B; immunoglobulin E, 37341-29-0; interleukin 13, 148157-34-0; lung surfactant, 99732-49-7; phosphatidylethanolamine, 1405-71-6; prednisolone, 50-24-8; Smad3 protein, 237417-78-6, 237417-96-8, 237418-00-7; lipid, 66455-18-3; Lipids Funding details: 115010 Funding details: Wellcome Trust, WT, 093500/Z/10/Z Funding details: European Commission, EC Funding text 1: The U-BIOPRED consortium receives funding from the European Union and from the European Federation of Pharmaceutical Industries and Associations as an Innovative Medicines Initiative Joint Undertaking (IMI JU) funded project (no. 115010). Additional funding for the analytical equipment was obtained from a Wellcome Trust equipment grant (no. 093500/Z/10/Z). LA - English DB - MTMT ER -